Etoposide Injection, Solution, Concentrate
NDC Package 68001-681-25

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Etoposide injection is etoposide is used to treat testicular cancer and certain forms of lung cancer (such as small cell lung cancer). This formulation utilizes a injection, solution, concentrate delivery system. Marketed by Bluepoint Laboratories, this product is identified by NDC 68001-681 and is authorized under FDA application ANDA074529.

Identification & Billing

NDC Package Code
68001-681-25
Package Description
1 VIAL, MULTI-DOSE in 1 CARTON / 5 mL in 1 VIAL, MULTI-DOSE
Product Code
68001-681
11-Digit Billing Format
68001068125
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Etoposide
Non-Proprietary Name
Etoposide
Substance Name
Etoposide
Dosage Form
Injection, Solution, Concentrate - A sterile preparation for parenteral use which, upon the addition of suitable solvents, yields a solution conforming in all respects to the requirements for Injections.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
ETOPOSIDE 20 mg/mL
Pharmacologic Class
Usage Information
Etoposide is used to treat testicular cancer and certain forms of lung cancer (such as small cell lung cancer). Etoposide works by slowing the growth of cancer cells.

Regulatory & Marketing

Labeler Name
Bluepoint Laboratories
Product Type
Human Prescription Drug
FDA Application #
ANDA074529
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
12-01-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68001-681-25 identifies a specific commercial package of 1 vial, multi-dose in 1 carton / 5 ml in 1 vial, multi-dose of Etoposide, a human prescription drug labeled by Bluepoint Laboratories. This injection, solution, concentrate is formulated for intravenous use and contains etoposide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bluepoint Laboratories on December 01, 2025. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Etoposide is used to treat testicular cancer and certain forms of lung cancer (such as small cell lung cancer). Etoposide works by slowing the growth of cancer cells.

How is this Bluepoint Laboratories product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68001068125. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68001-681-25
11-Digit CMS (5-4-2)
68001-0681-25

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.